Prescribing Patterns of Antihypertensives for Treatment-Naïve Patients in South Korea: From Korean NHISS Claim Data by 김신혜
Research Article
Prescribing Patterns of Antihypertensives for Treatment-Naı̈ve
Patients in South Korea: From Korean NHISS Claim Data
Sang Hyuck Kim,1 Dong Wook Shin ,2 Shinhye Kim,3 Kyungdo Han,4 Sang-hyun Park,4
Yul-Hee Kim,5 Shin-Ae Jeon,5 and Yong-Chol Kwon5
1Department of Family Medicine, Bumin Hospital, Seoul, Republic of Korea
2Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine,
Seoul, Republic of Korea
3Department of Family Medicine, Gangnam Severance Hospital, Seoul, Republic of Korea
4Department of Biostatistics, College of Medicine, Catholic University, Republic of Korea
5Medical Affairs, Pfizer Essential Health Business Unit, Pfizer Pharmaceuticals Korea Limited, Seoul, Republic of Korea
Correspondence should be addressed to Dong Wook Shin; dwshin.md@gmail.com
Received 22 January 2019; Revised 10 July 2019; Accepted 30 July 2019; Published 25 August 2019
Academic Editor: Tomohiro Katsuya
Copyright © 2019 Sang Hyuck Kim et al. +is is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Background. Several factors influence the choice of antihypertensive drugs. To facilitate the rational use of drugs it is important to
assess their prescription patterns over time.+is study aims to evaluate doctors’ prescribing patterns of antihypertensive drugs for
drug-näıve patients in South Korea.Methods. +e claims data of the Korean National Health Insurance Research Database from 1
January 2011 to 31 December 2015 were analyzed. +e data virtually cover the entire South Korean population. Antihypertensive
drugs were further subdivided into angiotensin receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEis),
calcium channel blockers (CCBs), beta-blockers (BBs), and thiazide diuretics. +e prescription pattern of antihypertensive drugs
and associated factors were assessed according to the patients’ characteristics, including associated comorbidities. Results. A total
of 2,919,162 subjects had started taking antihypertension medications during the study period. ARB was the most frequently
prescribed drug (51.6%) followed by CCB (45.0%), BB (18.5%), diuretics (17.0%), and ACEi (11.7%). Most patients were prescribed
with monotherapy (66.7%) rather than combination therapy (33.3%), and CCB was the most frequently prescribed monotherapy
drug (25.7%). For combination therapy, ARB+CCB was the most frequently prescribed combination, and the prescription
frequency was found to be increasing. In patients prescribed with combination therapy, most had been prescribed single-pill fixed-
dose combination. Conclusion. We identified the physicians’ prescription patterns of antihypertensive drugs for treatment-näıve
patients. +e findings of this study can lead to a rational, evidence-based, and cost-effective improvement of prescription patterns
in newly diagnosed hypertensive patients.
1. Introduction
Hypertension is a common chronic condition which is
associated with various complications including cardio-
vascular disease and chronic kidney disease. It remains that
hypertension is one of the most important preventable
conditions to reduce cardiovascular mortality [1]. Despite
this, the high and increasing prevalence of hypertension still
contributes to considerable socioeconomic burden globally
[2–4].
In order to choose the appropriate antihypertensive drug
among various available classes, several factors should be
considered, such as age and underlying comorbid conditions
[5–7]. Also, the type of antihypertensive drugs can affect
prescribing patterns as well as drug compliance [8–11].
+erefore, it is necessary to assess prescription patterns to
determine whether current prescription is reasonable, evi-
dence-based, and cost-effective [11]. Although there have
been several studies on prescription patterns of antihyper-
tensives in other countries, they are not relevant in the
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Korean context since prescription patterns are influenced by
time and region [9,10,12–14]. Furthermore, previously
conducted studies in Korea are either too old or not rep-
resentative (single hospital-based study) [15, 16].
+is study aimed at evaluating prescribing patterns of
antihypertensive drugs in patients who were prescribed
antihypertensive drugs for the first time.
2. Materials and Methods
2.1. Data Sources. +e claims data of the Korean National
Health Insurance Research Database (NHIRD) were ana-
lyzed. NHIRD contains qualification data, medical services
claim data, and pharmacy claim data. As such, the claims
data include patient information such as age, sex, household
income, residential regions, as well as diagnosis information
(by the International Classification of Diseases, 10th Re-
vision; ICD-10) and specific information of diagnostic tests,
procedures, and prescriptions.
In general, the Korean National Health Insurance Ser-
vice (NHIS) is the sole insurer providing a mandatory
universal health insurance which virtually covers the entire
Korean population (about 97% of total population) and a
medical aid program to those in the lowest income bracket
who are covered by government funding. We used the
nation-wide claims data which covered the South Korean
population over a 5-year period, from 1 January 2011 to 31
December 2015. Detailed insights into the advantages of this
data are described elsewhere [17, 18].
2.2. Study Population. From the whole Korean population
(N�∼50 million), patients who were newly diagnosed with
hypertension (ICD-10: I10, I11, I12, I13, or I15) and pre-
scribed with antihypertensive agents were included in this
study. We further confirmed that the study subjects did not
have any previous record of antihypertensive medication
during the prior 12months.
2.3. Variables
2.3.1. Antihypertensive Agents. Antihypertensive agents
were classified into 5major categories, including angiotensin
receptor blockers (ARB), angiotensin-converting enzyme
inhibitors (ACEi), calcium channel blockers (CCB), beta-
blockers (BB), and thiazide diuretics (including indapamide
and chlorthalidone), or other antihypertensive drugs.
Initial prescription was divided into single drug and
combination. Single drug was defined as the prescription of 1
class of antihypertensive at first prescription. Combination
was defined as prescription of 2 or more classes of anti-
hypertensives at first prescription and was further catego-
rized by single-pill fixed-dose drug and free combination
(multiple-pill combinations). Commonly used combina-
tions available commercially are specifically listed:
ARB+CCB, ARB+ thiazide, and ARB+CCB+ thiazide.
2.3.2. Comorbidities. Comorbidities were defined by ICD 10
codes: diabetes (ICD 10: E11-14), dyslipidemia (E78),
congestive heart failure (I50), coronary heart disease(I20-
25), stroke (I60 to I64, I67, and I69), chronic kidney disease
(N18), and cancer (CX) during the previous 1 year prior to
index date (first prescription of antihypertensive medica-
tion). +e Charlson comorbidity index was also assessed in
the same manner [16].
2.4. Statistical Analyses. +e baseline characteristics of hy-
pertensive patients who were newly prescribed with anti-
hypertensive medication were described using frequencies
and percentages or as means with standard deviation.
Descriptive statistics were calculated for patterns of first
prescriptions of antihypertensive medications. +e pro-
portion of each antihypertensive class was calculated
according to patient characteristics (age, sex, income level,
and place of residence), medical characteristics (the
Charlson comorbidity index and each comorbidity as de-
fined above), provider characteristics (level of hospital;
general hospital vs. hospital vs. clinic), and year of first
prescription.
Factors associated with choice of first prescription for
hypertension were investigated with a series of multivariate
logistic regression analyses including all of the aforemen-
tioned characteristics. Outcomes were (1) combination vs.
single, (2) choice of each drug class among single drug user
(exclusive to each other), (3) choice of each drug class among
all patients (not exclusive to each other), and (4) fixed-dose
combination vs. free combination for selected combinations.
Also, the trends of combination therapy according to the age
group, income level, and Charlson’s comorbidity index were
assessed by calculating the “p for trend.”
All analyses were performed using the SAS statistical
software (ver. 9.3, SAS Institute., Cary, NC, USA). All tests
were two-sided, and statistical significance was defined as a p
value <0.05.
2.5. Ethics Statement. +is study was reviewed and approved
by the Institutional Review Board of the Samsung Medical
Center (IRB No. SMC 2007-07-130). +e requirement for
informed consent was waived because this study is based on
routinely collected administrative or claims data.
3. Results
3.1. Baseline Characteristics. A total of 2,919,162 subjects
had started taking antihypertension medications during the
study period. 56.0% of these were male patients. +e mean
age of the study population was 53.0 (±14.5) years. Over half
of the study population resided in metropolitan areas. About
67.9% of subjects had 1 or more comorbidity as per the
Charlson comorbidity index. Subjects had various hyper-
tension-related comorbid conditions such as dyslipidemia
(27.6%), coronary heart disease (13.8%), diabetes (12.7%),
stroke, (4.6%), congestive heart failure (4.1%), and chronic
kidney disease (0.93%). +e annual incidence rate per year
was 1.24% in 2011, 1.20% in 2012, 1.13% in 2013, 1.05% in
2014, and 1.12% in 2015, respectively (Table 1).
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3.2. Frequency and Trend of the Prescription. Around two-
thirds of the study population was prescribed with mono-
therapy at first prescription, and one-third was prescribed
with initial combination therapy (Table 2). CCB was the
most frequently prescribed monotherapy drug (25.70%),
followed by ARB (24.45%) and BB (11.88%). +e proportion
of ARB and BB prescriptions increased during the study
period, while CCB and ACEI decreased.+eARB+CCBwas
the most frequently prescribed combination (12.59%) and
was found to be increasing, while ARB+ thiazide (9.79%)
was decreasing during the study period (Table 3). Among the
5 drug classes, ARB was the most frequently prescribed drug
(51.61%), followed by CCB (45.03%), BB (18.48%), thiazide
diuretics (17.01%), and ACEi (3.11%). Initial drug choice
differed by comorbidities, e.g., 64.74% of diabetes patients
initiated with ARB, while 54.18% of CHF patients were
initiated with beta-blockers. In CKD patients, 59.82% re-
ceived ARB and 8.34% received ACEi (Table 4).
A comparison of prescription rates between 2011 and
2015 revealed an increase of 4% in the prescription rate of
ARB and an 8% increase in the rate of thiazide prescription
(Figure 1).
3.3. Trend of Single-Pill Fixed-Dose Combination. Among
combination therapy users, most patients were prescribed a
single-pill fixed-dose combination (83.73% for ARB+CCB
and 96.46% for ARB+ thiazide, respectively) in an increasing
proportion during the study period (Table 3).
3.4. Trend and Factors Associated with Initial Combination
7erapy. Female patients were less likely to be prescribed
with combination therapy at first prescription (adjusted
odds ratio: 0.764, 95% CI 0.760–0.768). Having congestive
heart failure, dyslipidemia, CHD, stroke, CKD, and cancer
was slightly associated with initiation with combination
therapy, while it was opposite with diabetes mellitus. Pri-
mary clinics prescribed combination antihypertensive drugs
more frequently than secondary hospitals and general
hospitals. Initial combination therapy decreased slightly
during the study period (35.81 in year 2011 to 32.53% in year
2015). +ere was no significant trend by the age group or
Charlson comorbidity index (Table 2).
4. Discussion
In this study, physicians’ prescription patterns of antihy-
pertensive drugs for treatment-naı̈ve patients were identified
using the National Health Insurance claims data. +e
strength of this study is its generalizability, as it uses claims
data collected from the entire South Korean population and
assess data over a 5-year period which allows for the
identification of trends in prescription patterns.
In a previous study of prescription patterns in Korea
conducted in 2009, CCB was the most frequently prescribed
antihypertensive (64.4%), followed by diuretics (44.6%),
ARB (33.3%), BB (21.6%), and ACEi (11.7%) [16]. In this
study, the corresponding figures were 45.0%, 17.0%, 51.6%,
18.5%, and 3.1%, respectively. +is shows that the use of
ARB has significantly increased over time, while use of other
antihypertensive classes decreased.
Similarly, we also identified that the use of thiazide
diuretics and ACEi was decreasing and ARB use was in-
creasing during the study period. Although CCB was the
most frequently prescribed drug for monotherapy, overall
ARB was the most frequently prescribed class of antihy-
pertensive drugs since the prescription of ARB for combi-
nation therapy also increased.
+e prescription of CCBs and ARBs increased world-
wide over the past several years [11]. Especially, CCBs and
Table 1: Baseline characteristics of newly diagnosed hypertension















Medical aid 112,217 3.84
Q1 (low) 766,378 26.25
Q2 696,643 23.86
Q3 663,524 22.73











General hospital 924,592 31.67
Hospital 330,928 11.34
Clinic 1,560,700 53.46




Congestive heart failure 120,749 4.14
Ischemic heart failure 401,547 13.76
Stroke 135,569 4.64
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ARBs were the most frequently prescribed antihypertensives
in the nearby countries of Japan and China [19, 20]. +ere
may be several reasons for this changing prescription trend.
+e former JNC7 recommended diuretics as the first-line
therapy [6, 21], but recent guidelines including regional
Korean guidelines announced not only diuretics but also
ARBs and CCBs as the first-line treatment, and the corre-
sponding drug utilization appears to have changed
[5, 7, 22, 23]. Moreover, although these guidelines included
the diuretics as first-line drugs, in East Asian countries
including Japan and China, the prescription rate of diuretics
for hypertension is lower than that in the United States
[19, 20, 24]. Frequent adverse events with the use of diuretics
and associated low compliance may account for the low
prescription rate [12, 19]. Also, relatively low ACEi pre-
scription presumably reflects the occurrence of frequent side
effects in the Asian population such as dry cough [25]. +e
decreased use of ACEi might account for the increased use of
Table 2: Prescription pattern by the number of drug classes, n (%).
Single drug class Combination Combination (vs. single)
OR (95% CI)
Overall 1,947,796 (66.72) 971366 (33.28)
Age (mean± SD) 53.13± 14.48 52.84± 14.52
<20 29,435 (65.09) 15,787 (34.91) 1.214 (1.190–1.239)
20–29 72,099 (75.51) 23,390 (24.49) 0.650 (0.640–0.661)
30–39 202,994 (66.88) 100,529 (33.12) 0.957 (0.948–0.965)
40–49 458,093 (64.2) 255,431 (35.8) 1.094 (1.087–1.101)
50–59 574,198 (66.28) 292,172 (33.72) 1 (ref.)
60–69 348,811 (68.57) 159,851 (31.43) 0.900 (0.894–0.907)
70–79 202,102 (68.56) 92,669 (31.44) 0.913 (0.905–0.922)
≥80 60,064 (65.57) 31,537 (34.43) 1.041 (1.026–1.057)
Sex
Male 1,048,973 (64.21) 584,795 (35.79) 1 (ref.)
Female 898,823 (69.93) 386,571 (30.07) 0.764 (0.760–0.768)
Income
Medical aid 75,202 (67.01) 37,015 (32.99) 1.133 (1.118–1.149)
Q1(Low) 499,304 (65.15) 267,074 (34.85) 1.220 (1.212–1.229)
Q2 457,765 (65.71) 238,878 (34.29) 1.184 (1.175–1.193)
Q3 444,104 (66.93) 219,420 (33.07) 1.115 (1.107–1.123)
Q4(High) 471,421 (69.29) 208,979 (30.71) 1 (ref.)
Residence
Metropolitan 1,172,041 (67.31) 569,263 (32.69) 1 (ref.)
City 549,150 (65.86) 284,617 (34.14) 1.068 (1.062–1.074)
Rural 226,605 (65.86) 117,486 (34.14) 1.077 (1.069–1.086)
Charlson’s comorbidity index
0 616,812 (65.75) 321,322 (34.25) 1.050 (1.041–1.058)
1 531,229 (67.13) 260,159 (32.87) 0.999 (0.992–1.007)
2 338,054 (67.95) 159,469 (32.05) 0.962 (0.955–0.970)
≥3 461,701 (66.71) 230,416 (33.29) 1 (ref.)
Comorbidity
Diabetes 258,962 (69.71) 112,515 (30.29) 0.816 (0.810–0.823)
Dyslipidemia 528,199 (65.51) 278,047 (34.49) 1.107 (1.101–1.114)
Congestive heart failure 65,091 (53.91) 55,658 (46.09) 1.890 (1.867–1.914)
Ischemic heart failure 257,083 (64.02) 144,464 (35.98) 1.132 (1.123–1.140)
Stroke 87,896 (64.83) 47,673 (35.17) 1.141 (1.128–1.155)
Chronic kidney disease 17,263 (63.32) 10,000 (36.68) 1.193 (1.163–1.224)
Cancer 29,331 (65.73) 15,295 (34.27) 1.177 (1.153–1.201)
Provider type
General hospital 641,364 (69.37) 283,228 (30.63) 0.767 (0.763–0.772)
Hospital 216,869 (65.53) 114,059 (34.47) 0.964 (0.956–0.971)
Clinic 1019,985 (65.35) 540,715 (34.65) 1 (ref.)
Other 69,578 (67.59) 33,364 (32.41) 0.900 (0.888–0.913)
Year of diagnosis
2011 402,660 (64.19) 224,589 (35.81) 1 (ref.)
2012 395,541 (66.15) 202,371 (33.85) 0.915 (0.909–0.922)
2013 395,450 (68.36) 183,029 (31.64) 0.824 (0.818–0.831)
2014 364,782 (67.74) 173,686 (32.26) 0.843 (0.837–0.850)
2015 389,363 (67.47) 187,691 (32.53) 0.850 (0.843–0.856)
OR: odds ratio; CI: confidence interval.















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6 International Journal of Hypertension
the alternative drug, the ARB. In addition, more favorable
adherence and less frequent side effects might increase the
use of ARB [12]. Lim et al. had already reported the increase
in prescriptions for ARBs and a decrease for diuretics in
Korea [15]. However, as the study was based on a single
tertiary hospital, the results cannot be generalized to the
overall population. Moreover, the study included patients
who were already taking antihypertensives, so the pro-
portion of combination therapy was higher than that of the
present study (50.9% vs. 33.3%). Although the prescription
patterns of antihypertensives differ across countries
[11, 19, 20], the proportion of initial combination therapy of
the present study seems to be low when compared to nearby
countries [26]. Because intensive initial treatment for hy-
pertension is recommended nowadays, an effort to increase
the proportion of initial combination therapy may be
warranted [5, 27]. Considering patient compliance, a single-
pill, fixed-dose combination is a good option [28].
In some groups, other classes rather than CCBs or ARBs
were prescribed frequently. In those less than 20 years of age,
the use of ACEi and BBs was more frequent. However, it is
unclear why ACEi and BBs were used more frequently than
in other age groups. Certain underlying conditions such as
diabetes, proteinuria, or migraines as well as physician’s
Table 4: Prescription pattern by the drug classes, either included in monotherapy or combination therapy, n (%).
ARB ACEI BETA CCB Diuretics
Overall 150,6561 (51.61) 90,784 (3.11) 539,372 (18.48) 1,314,597 (45.03) 496,634 (17.01)
Age (mean± SD) 53.01± 12.74 53.4± 17.74 51.43± 16.17 54.32± 13.73 54.07± 13.81
<20 6,928 (15.32) 5,564 (12.30) 15,015 (33.20) 7,479 (16.54) 3,092 (6.84)
20–29 31,458 (32.94) 2,561 (2.68) 35,064 (36.72) 32,134 (33.65) 13,038 (13.65)
30–39 156,422 (51.54) 7,447 (2.45) 66,968 (22.06) 130,704 (43.06) 48,151 (15.86)
40–49 415,900 (58.29) 17,660 (2.48) 118,228 (16.57) 315,763 (44.25) 124,418 (17.44)
50–59 476,338 (54.98) 24,123 (2.78) 142,677 (16.47) 393,807 (45.45) 148,443 (17.13)
60–69 251,389 (49.42) 17,004 (3.34) 87,818 (17.26) 241,238 (47.43) 86,640 (17.03)
70–79 131,138 (44.49) 11,737 (3.98) 55,469 (18.82) 145,191 (49.26) 54,624 (18.53)
≥80 36,988 (40.38) 4,688 (5.12) 18,133 (19.80) 48,281 (52.71) 18,228 (19.90)
Sex
Male 904,778 (55.38) 60,192 (3.68) 275,763 (16.88) 775,090 (47.44) 251,286 (15.38)
Female 601,783 (46.82) 30,592 (2.38) 263,609 (20.51) 539,507 (41.97) 245,348 (19.09)
Income
Medical aid 46,315 (41.27) 3,943 (3.51) 27,160 (24.20) 46,751 (41.66) 19,055 (16.98)
Q1 (low) 398,887 (52.05) 22,550 (2.94) 139,374 (18.19) 353,498 (46.13) 138,079 (18.02)
Q2 363,159 (52.13) 20,640 (2.96) 126,485 (18.16) 315,653 (45.31) 121,217 (17.40)
Q3 346,565 (52.23) 21,268 (3.21) 119,086 (17.95) 299,447 (45.13) 111,549 (16.81)
Q4 (high) 351,635 (51.68) 22,383 (3.29) 127,267 (18.7) 299,248 (43.98) 106,734 (15.69)
Residence
Metropolitan 909,496 (52.23) 53,311 (3.06) 320,725 (18.42) 778,121 (44.69) 282,095 (16.20)
City 430,908 (51.68) 25,320 (3.04) 156,480 (18.77) 375,042 (44.98) 148,404 (17.80)
Rural 166,157 (48.29) 12,153 (3.53) 62,167 (18.07) 161,434 (46.92) 66,135 (19.22)
Charlson comorbidity index
0 502,861 (53.60) 12,245 (1.31) 137,490 (14.66) 456,193 (48.63) 163,131 (17.39)
1 411,171 (51.96) 18,536 (2.34) 136,449 (17.24) 355,466 (44.92) 138,614 (17.52)
2 252,680 (50.79) 19,096 (3.84) 97,293 (19.56) 212,683 (42.75) 85,095 (17.10)
≥3 339,849 (49.10) 40,907 (5.91) 168,140 (24.29) 290,255 (41.94) 109,794 (15.86)
Comorbidity
Diabetes 240,501 (64.74) 21,283 (5.73) 53,265 (14.34) 127,538 (34.33) 55,124 (14.84)
Dyslipidemia 465,523 (57.74) 44,577 (5.53) 155,768 (19.32) 331,832 (41.16) 124,074 (15.39)
Congestive heart failure 45,540 (37.71) 22,783 (18.87) 65,416 (54.18) 37,246 (30.85) 16,936 (14.03)
Ischemic heart failure 148,348 (36.94) 40,612 (10.11) 161,776 (40.29) 178,876 (44.55) 44,121 (10.99)
Stroke 67,621 (49.88) 6,568 (4.84) 34,636 (25.55) 66,925 (49.37) 19,360 (14.28)
Chronic kidney disease 16,310 (59.82) 2,274 (8.34) 5,974 (21.91) 12,220 (44.82) 3,257 (11.95)
Cancer 13,353 (29.92) 1,531 (3.43) 11,312 (25.35) 24,520 (54.95) 4,385 (9.83)
Provider type
General hospital 350,910 (37.95) 67,357 (7.29) 316,088 (34.19) 406,074 (43.92) 81,064 (8.77)
Hospital 161,403 (48.77) 5,958 (1.80) 57,090 (17.25) 176,623 (53.37) 55,586 (16.80)
Clinic 946,054 (60.62) 14,843 (0.95) 160,542 (10.29) 668,985 (42.86) 339,547 (21.76)
Others 48,194 (46.82) 2,626 (2.55) 5,652 (5.49) 62,915 (61.12) 20,437 (19.85)
Year
2011 312,074 (49.75) 21,853 (3.48) 115,374 (18.39) 291,626 (46.49) 132,317 (21.09)
2012 306,353 (51.24) 20,206 (3.38) 112,748 (18.86) 257,977 (43.15) 117,653 (19.68)
2013 300,076 (51.87) 18,703 (3.23) 104,476 (18.06) 252,941 (43.73) 94,175 (16.28)
2014 280,036 (52.01) 15,514 (2.88) 101,408 (18.83) 245,769 (45.64) 76,045 (14.12)
2015 308,022 (53.38) 14,508 (2.51) 105,366 (18.26) 266,284 (46.15) 76,444 (13.25)
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preference considering adverse drug effects may affect the
prescription pattern in children and adolescents [29, 30].
Although several guidelines excluded beta-blocker as a first-
line antihypertensive drug [5, 7], the prescription rate of the
drug was relatively stable during the study period. It may be
due to the presence of comorbid conditions such as ischemic
heart disease and arrhythmia, in which the use of beta-
blockers is inevitable. However, overall beta-blocker use was
found to be relatively low. Unlike the JNC 7 guideline, the
JNC 8 guideline did not suggest compelling indications of
each antihypertensive drug classes. However, there are
several clinical situations which make a specific antihy-
pertensive class preferred to others. For example, JNC 7 and
domestic hypertension guidelines in Korea recommend
beta-blocker as an initial choice for hypertension in
congestive heart failure patients [16].+erefore, unlike other
conditions, beta-blocker may be most frequently prescribed
for congestive heart failure patients in the present study,
suggesting that clinical guidelines are reflected in pre-
scription of Korean physicians.
On the contrary, we also observed some gaps between
the guidelines and clinical practice. According to the JNC 8
guideline, the use of ARB or ACEi was recommended es-
pecially in those with chronic kidney diseases [7]. However,
the prescription rate of ARB or ACEi in the chronic kidney
disease patients was not optimal and was only 68.2%. Even
though there can be rational reasons not to use these drugs, a
substantial portion of chronic kidney disease patients may
lose the chance to prevent or delay disease progression.













































































Figure 1: Prescription pattern and trend of the antihypertensive drugs. (a) Prescription pattern including combination therapy, (b) trend
including combination therapy, (c) prescription number by drug classes, and (d) trend by drug classes.
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patterns based on their own experience rather than scientific
evidences [11]. Further studies are needed to assess and
decrease these gaps of prescription pattern.
Overall, the prescription rate of combination therapy
was slightly decreasing throughout the study period. In JNC
8 guideline, patients with stage 2 hypertension (BP> 160/
100) are recommended to receive combination therapy from
the first prescription [7]. In Korea, the national health
screening program is offered biennially and more hyper-
tension is diagnosed at an earlier stage due to increasing
participation rates [31]. However, considering the relatively
low proportion of patients achieving the target blood
pressure level (less than 70%) [32], more aggressive treat-
ment for hypertensive patients using combination therapy is
warranted.
For initial combination therapy, most patients received
single-pill fixed-dose combination drugs and this was an
increasing trend. +e use of single-pill fixed-dose combi-
nation is advantageous in terms of the price of a single-pill
combination and the advantage of drug adherence and blood
pressure control [6, 7, 11, 33], suggesting a trend toward the
favorable prescription pattern.
+ere are several limitations to be considered in this
study. First, there is possibility of false claims of hyper-
tension for reimbursement purpose. For example, beta-
blockers are often effective in chronic headache but not
reimbursed in Korea for that purpose. So, the physician
might have entered the hypertension disease code for
making the drug covered by the NHI. Second, we do not
have detailed clinical information for each prescription and
could not determine the appropriateness of drug choice in
individual basis.
5. Conclusions
We identified overall prescription patterns of antihyper-
tensives for treatment-naı̈ve patients in South Korea. +e
findings can lead to a rational, evidence-based, and cost-
effective improvement of prescription patterns in newly
diagnosed hypertensive patients.
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